Planning a Multi-Center Trial of Interferon-gamma in Trauma Patients

计划在创伤患者中进行干扰素-γ 多中心试验

基本信息

  • 批准号:
    8366828
  • 负责人:
  • 金额:
    $ 17.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-01 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Based on our analysis of severe blunt trauma patients enrolled in the "Inflammation and the Host Response to Injury" Program, our investigators propose that a large proportion of patients who would generally meet the inclusion criteria for a study of severely injured patients are not in need of immunomodulatory therapy and are unlikely to benefit from such therapies (IFN?, ¿-glucan or immunoglobulin). In contrast, there exists a subset of patients who will have a protracted clinical course, and would benefit from interventional therapies with biological-response modifiers. Inclusion of the former patients in such a clinical trial who would either not benefit or might be harmed by such therapies has made it extremely difficult to identify the beneficial effects of these interventions in the latter subset of patients who would be responsive to these therapies. We believe that this failure to identify those patients a priori who may actually benefit from intervention ("personalized therapies") is one reason that clinical trials in trauma and sepsis have failed. Therefore, it is absolutely essential that a rapid prognostic be developed and used to prospectively identify those severely injured patients who would be good candidates for the immunomodulatory intervention. The overall goal of the proposed clinical trial would be to determine whether administration of IFN? will alter the clinical trajectory in a subgroup of severely injured patient identified by a prognostic indicator based on a genomic signature likely to have an adverse clinical outcome and who would benefit from such therapies. Blood samples will be collected with the goal being to determine whether rh-IFN? treatment restores an improved genomic signature associated with better outcomes. A primary clinical goal is to determine whether rh-IFN? reduces "time to recovery" and increases "organ-failure free days" in this at-risk population. PUBLIC HEALTH RELEVANCE: We propose to organize a clinical trial to determine whether administration of interferon-¿ will alter the clinical trajectory in a subgroup of severely injured patients, identified by a prognostic indicator based in part on the leukocyte genomic response to trauma as being likely to have an adverse clinical outcome and benefit from such therapies. Our overarching hypothesis is that changes in the blood leukocyte genome can be used to predict distant clinical outcomes and to detect response to therapies in patients, not only with severe trauma and critical illness. A primary objective is to determine whether rhIFN-? reduces "time to recovery" and increases "organ-failure free days" in the subgroup of patients identified by the prognostic test to be at increased risk.
描述(申请人提供):基于我们对“炎症和宿主损伤反应”计划中登记的严重钝性创伤患者的分析,我们的研究人员提出,通常符合严重损伤患者研究纳入标准的很大一部分患者不需要免疫调节治疗,并且不太可能从此类治疗(干扰素、β-葡聚糖或免疫球蛋白)中受益。相比之下,有一部分患者将具有长期的临床病程,并将受益于具有生物反应调节剂的介入治疗。将不会受益或可能受到此类疗法伤害的前一类患者纳入这样的临床试验,使得在后者中确定这些干预措施的有益效果变得极其困难。 对这些疗法有反应的患者的子集。我们认为,未能事先确定哪些患者实际上可能从干预(“个性化治疗”)中受益,这是创伤和败血症临床试验失败的原因之一。因此,开发一种快速的预后指标并用于前瞻性地识别哪些严重损伤的患者将是免疫调节干预的良好候选者是绝对必要的。拟议的临床试验的总体目标将是确定是否给予干扰素?将改变严重受伤患者亚组的临床轨迹,该亚组由基于基因组签名的预后指标确定,该基因组签名可能具有不利的临床结果,谁将从这种治疗中受益。将采集血样,目的是确定是否存在rh-干扰素?治疗恢复了与更好结果相关的改进的基因组签名。一个主要的临床目标是确定rh-干扰素?在这一高危人群中,减少了“恢复时间”,增加了“无器官衰竭的天数”。 公共卫生相关性:我们建议组织一项临床试验,以确定使用干扰素是否会改变严重创伤亚组的临床轨迹 部分基于白细胞基因组对创伤的反应的预后指标确定的患者可能会有不利的临床结果,并从此类治疗中受益。我们的主要假设是,血白细胞基因组的变化可以用来预测遥远的临床结果,并检测患者对治疗的反应,而不仅仅是严重创伤和危重疾病。主要目的是确定重组人干扰素-?在被预后测试确定为风险增加的患者亚组中,缩短了“恢复时间”,增加了“器官衰竭无衰竭天数”。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RONALD GARY TOMPKINS其他文献

RONALD GARY TOMPKINS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RONALD GARY TOMPKINS', 18)}}的其他基金

Bedside Genomics in Severe Trauma
严重创伤的床边基因组学
  • 批准号:
    8550810
  • 财政年份:
    2012
  • 资助金额:
    $ 17.21万
  • 项目类别:
Bedside Genomics in Severe Trauma
严重创伤的床边基因组学
  • 批准号:
    8275159
  • 财政年份:
    2012
  • 资助金额:
    $ 17.21万
  • 项目类别:
Inflammation and the Host Responses to Injury
炎症和宿主对损伤的反应
  • 批准号:
    7939189
  • 财政年份:
    2009
  • 资助金额:
    $ 17.21万
  • 项目类别:
STUDY OF GLUTAMINE AND GLUTAMATE METABOLISM IN HEALTHY SUBJECTS
健康受试者中谷氨酰胺和谷氨酸代谢的研究
  • 批准号:
    7731322
  • 财政年份:
    2008
  • 资助金额:
    $ 17.21万
  • 项目类别:
Core C1: Data Interpretation Core
核心 C1:数据解释核心
  • 批准号:
    7195404
  • 财政年份:
    2006
  • 资助金额:
    $ 17.21万
  • 项目类别:
Core G: Patient-Oriented Research Core
核心 G:以患者为中心的研究核心
  • 批准号:
    7195417
  • 财政年份:
    2006
  • 资助金额:
    $ 17.21万
  • 项目类别:
Core A: Administration Core
核心 A:管理核心
  • 批准号:
    7195396
  • 财政年份:
    2006
  • 资助金额:
    $ 17.21万
  • 项目类别:
Core B: Information Dissemination & Data Coordination Core
核心B:信息传播
  • 批准号:
    7195399
  • 财政年份:
    2006
  • 资助金额:
    $ 17.21万
  • 项目类别:
Animal Research Core
动物研究核心
  • 批准号:
    6794556
  • 财政年份:
    2004
  • 资助金额:
    $ 17.21万
  • 项目类别:
Human Subjects Core
人类受试者核心
  • 批准号:
    6794554
  • 财政年份:
    2004
  • 资助金额:
    $ 17.21万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 17.21万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.21万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 17.21万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.21万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 17.21万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.21万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 17.21万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 17.21万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 17.21万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.21万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了